OM
SMTI icon

Opaleye Management’s Sanara MedTech SMTI Stock Holding History

Opaleye Management’s Portfolio SMTI Stock Details SMTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-225,000
Closed -$7.01M – 58
2021
Q1 		$7.01M Buy
+225,000
New +$7.8M 1.03% 31

Other funds holding SMTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
NRC
North Run Capital Boston, Massachusetts $43.5M AUM 38.24% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.37B AUM 71.68% 1-Year Est. Return
SIC
Salem Investment Counselors Winston Salem, North Carolina $4.03B AUM 61.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Opaleye Management's SMTI Position: Q2 2021 in Review

Opaleye Management sold out of Sanara MedTech (SMTI) in Q2 2021, closing a stake of 225,000 shares — an estimated $7.01M sold.

Opaleye Management first reported a position in SMTI in Q1 2021 and held it in 1 quarter. The position peaked at $7.01M in Q1 2021. 21 funds tracked by Wall St. Rank hold SMTI as of Q2 2021.

  • Opaleye Management reported no remaining Sanara MedTech position as of Q2 2021 after selling out during the quarter.
  • Opaleye Management sold 225,000 Sanara MedTech shares in Q2 2021, an estimated $7.01M.
  • Opaleye Management first reported a position in Sanara MedTech in Q1 2021 and held it in 1 quarter.
  • Opaleye Management's Sanara MedTech position peaked at $7.01M in Q1 2021.
  • 21 funds tracked by Wall St. Rank held Sanara MedTech as of Q2 2021.

Based on Opaleye Management's 13F filing for Q2 2021, filed 16 Aug 2021.